retatrutide heartburn Unapproved weight loss drug causes extreme side effects Retatrutide: The "Triple G" Peptide

The Triple-Agonist Breakthrough Retatrutide (LY3437943), developed by Eli Lilly, is an investigational triple-agonist peptide that activates three metabolic receptors simultaneously: GLP-1, GIP, and the glucagon receptor

in the treatment-policy estimand analysis the 14 mg oral-semaglutide group had mean A1C reductions from baseline of -1.3%, -1.2%, and -1.1% at 26, 52, and 78 weeks, respectively

In the social media study, we report 8 major themes including effects of medications (30%)

When Pinto has a patient who asks about weaning off their GLP-1 or spacing out dosing, he is very receptive to the conversation

Gradual dose escalation and eating smaller, less fatty meals help minimize this side effect

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 10 , 403412